Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KMO | O15229 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27840823 | 0.96 | AKR1C3 (0.65) | AKR1C3NR4A2KMT2AKMOCA12 | |
| SCHEMBL10222477 | 0.86 | AKR1C3 (0.61) | AKR1C3NR4A2KMT2AKMOCA12 | |
| SCHEMBL289656 | 0.84 | KMT2A (0.57) | KMT2ANPC1RAB9A | |
| SCHEMBL191052 | 0.82 | PARP1 (0.65) | AKR1C3KMT2A | |
| SCHEMBL68858 | 0.81 | AKR1C3 (0.92) | AKR1C3NR4A2KMT2AKMOCA12 | |
| SCHEMBL30449599 | 0.81 | AKR1C3 (0.92) | AKR1C3NR4A2KMT2AKMOCA12 | |
| SCHEMBL30307454 | 0.81 | AKR1C3 (0.92) | AKR1C3NR4A2KMT2AKMOCA12 | |
| SCHEMBL177641 | 0.79 | SMN1; SMN2 (0.55) | KMT2AMRGPRX4NPC1RAB9A | |
| SCHEMBL1635565 | 0.79 | AKR1C3 (0.88) | AKR1C3NR4A2KMT2AKMOMRGPRX4 | |
| SCHEMBL2977712 | 0.79 | AKR1C3 (0.74) | AKR1C3NR4A2KMT2AKMOCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115364895-B | Ionic liquid gel catalyst and preparation method and application thereof | 河北科技大学 | 2024-03-26 | — | — | CN | claimed |
| US-12435042-B2 | Process for the preparation of key intermediates for the synthesis of Eltrombopag or salt thereof | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2025-10-07 | — | — | US | disclosed |
| CN-115364895-B | Ionic liquid gel catalyst and preparation method and application thereof | 河北科技大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-116903869-A | Zr-UiO-66-BA material, preparation method, application and saccharomyces cerevisiae concentration detection method | 贵州茅台酒股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20220298116-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF | F.l.S. - FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2022-09-22 | — | — | US | disclosed |
| CN-114727954-A | Wet packed soft hydrogel ocular inserts | 爱尔康公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3994126-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2022-05-11 | — | — | EP | disclosed |
| US-11262349-B2 | Multiplexed immune cell assays on a micropillar/microwell chip platform | CLEVELAND STATE UNIVERSITY (US) | 2022-03-01 | — | — | US | disclosed |
| US-11008323-B2 | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2021-05-18 | — | — | US | disclosed |
| WO-2021001044-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2021-01-07 | — | — | WO | disclosed |
| WO-2003029215-A1 | 4[PIPERIDIN-4-YLIDEN-(3-CARBAMOYLPHENYL)METHYL] BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, SPINAL INJURIES OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-4659817-A | FLUORESCENT DYES; STAIN FOR LIVING CELLS, PROTEINS AND FABRIC, THERAPEUTIC AGENTS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1987-04-21 | — | — | US | disclosed |
| US-4496722-A | STAINING CELLS, PROTEINS, FABRICS, AND PAPER; ENZYME AND IMMUNOASSAY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1985-01-29 | — | — | US | disclosed |
| EP-0110879-A1 | REPORTER COMPOUNDS | The Children's Medical Center Corporation (US) | 1984-06-20 | — | — | EP | disclosed |
| WO-1983004255-A1 | REPORTER COMPOUNDS | THE CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 1983-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435042-B2 | Process for the preparation of key intermediates for the synthesis of Eltrombopag or salt thereof | HABP2, F5, THPO | AKR1C3 414/4885NR4A2 4403/4885KMT2A 1150/4885 |
| US-20220298116-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF | HABP2, F5, THPO | AKR1C3 414/4885NR4A2 4403/4885KMT2A 1150/4885 |
| US-11008323-B2 | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors | GRM3, GRM1, GRM2 | AKR1C3 2346/4885NR4A2 124/4885KMT2A 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.